High mobility group box 1 complexed with heparin induced angiogenesis in a matrigel plug assay by Wake, Hidenori et al.
Acta Medica Okayama
Volume 63, Issue 5 2009 Article 5
OCTOBER 2009
High mobility group box 1 complexed with
heparin induced angiogenesis in a matrigel
plug assay
Hidenori Wake∗ Shuji Mori† Keyue Liu‡
Hideo K. Takahashi∗∗ Masahiro Nishibori††
∗Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry
and Pharmaceutical Sciences,
†Shujitsu University, School of Pharmacy,
‡Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry
and Pharmaceutical Sciences,
∗∗Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry
and Pharmaceutical Sciences,
††Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry
and Pharmaceutical Sciences, mbori@md.okayama-u.ac.jp
Copyright c©1999 OKAYAMA UNIVERSITY MEDICAL SCHOOL. All rights reserved.
High mobility group box 1 complexed with
heparin induced angiogenesis in a matrigel
plug assay
Hidenori Wake, Shuji Mori, Keyue Liu, Hideo K. Takahashi, and Masahiro
Nishibori
Abstract
Angiogenesis involves complex processes mediated by several factors and is associated with
inflammation and wound healing. High mobility group box 1 (HMGB1) is released from necrotic
cells as well as macrophages and plays proinflammatory roles. In the present study, we examined
whether HMGB1 would exhibit angiogenic activity in a matrigel plug assay in mice. HMGB1
in combination with heparin strongly induced angiogenesis, whereas neither HMGB1 nor hep-
arin alone showed such angiogenic activity. The heparin-dependent induction of angiogenesis by
HMGB1 was accompanied by increases in the expression of tumor necrosis factor-alpha (TNF-
alpha) and vascular endothelial growth factor-A120 (VEGF-A120). It is likely that the depen-
dence of the angiogenic activity of HMGB1 on heparin was due to the efficiency of the diffusion
of the HMGB1-heparin complex from matrigel to the surrounding areas. VEGF-A165 possessing
a heparin-binding domain showed a pattern of heparin-dependent angiogenic activity similar to
that of HMGB1. The presence of heparin also inhibited the degradation of HMGB1 by plasmin
in vitro. Taken together, these results suggested that HMGB1 in complex with heparin possesses
remarkable angiogenic activity, probably through the induction of TNF-alpha and VEGF-A120.
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Angiogenesis involves complex processes mediated by several factors and is associated with inﬂamma-
tion and wound healing.  High mobility group box 1 (HMGB1) is released from necrotic cells as well as 
macrophages and plays proinﬂammatory roles.  In the present study,  we examined whether HMGB1 
would exhibit angiogenic activity in a matrigel plug assay in mice.  HMGB1 in combination with hepa-
rin strongly induced angiogenesis,  whereas neither HMGB1 nor heparin alone showed such angiogenic 
activity.  The heparin-dependent induction of angiogenesis by HMGB1 was accompanied by increases 
in the expression of tumor necrosis factor-α (TNF-α) and vascular endothelial growth factor-A120 
(VEGF-A120).  It is likely that the dependence of the angiogenic activity of HMGB1 on heparin was due 
to the eﬃciency of the diﬀusion of the HMGB1-heparin complex from matrigel to the surrounding 
areas.  VEGF-A165 possessing a heparin-binding domain showed a pattern of heparin-dependent angio-
genic activity similar to that of HMGB1.  The presence of heparin also inhibited the degradation of 
HMGB1 by plasmin in vitro.  Taken together,  these results suggested that HMGB1 in complex with 
heparin possesses remarkable angiogenic activity,  probably through the induction of TNF-α and 
VEGF-A120.
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ngiogenesis is an essential process by which new 
blood vessels are formed and accompanies 
embryonic development,  inﬂammation and wound heal-
ing.  Angiogenesis may also be involved in several 
disease conditions,  including cancers,  rheumatic 
arthritis,  diabetic retinopathy and atherosclerosis.  
The process of angiogenesis appears to be under the 
control of a complex system consisting of proangio-
genic and antiangiogenic factors.  From the cellular 
perspective,  angiogenesis is a series of processes that 
induce the proliferation and migration of vascular 
endothelial cells (ECs),  in association with the activa-
tion of macrophages.  These cells together with 
stromal cells produce active substances such as matrix 
metalloproteinases (MMPs),  a variety of cytokines 
and growth factors [1-3].
　 High mobility group box 1 (HMGB1),  a non-histone 
nuclear protein involved in maintaining the architec-
tural structure of DNA and the regulation of tran-
scription,  is secreted from necrotic cells and activated 
macrophages.  Once released into the extracellular 
space,  HMGB1 acts as a cytokine [4-8].  HMGB1 is 
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widely distributed in all types of cells and is highly 
conserved throughout species [9].  HMGB1 has a 
unique structure consisting of 3 domains.  The A-box 
and B-box domains are rich in basic amino acids and 
bind to DNA,  while the C-terminal domain is com-
posed of acidic amino acid clusters [10].  It has been 
suggested that amino acids 6-12 bind to heparin,  and 
that amino acids 150-183 bind to the receptor for 
advanced glycation end products (RAGE) [11,  12].  
The expression of HMGB1 is increased in inﬂamma-
tory conditions such as sepsis [13],  atherosclerosis 
[14] and rheumatic arthritis [15].  HMGB1 is also 
secreted from several tumor cells [16-20].  Secreted 
HMGB1 may bind to RAGE,  toll-like receptor 2 
(TLR2) and toll-like receptor 4 (TLR4) expressed on 
the surfaces of monocytes/macrohpages,  and such 
bindings activate NF-κB [21-23],  thereby facilitating 
the inﬂammatory response through the expression and 
secretion of inﬂammatory cytokines (tumor necrosis 
factor-α (TNF-α),  IL-1α,  IL-1β,  IL-6,  IL-8,  etc. ) 
[24].  In addition,  HMGB1 may be closely related to 
angiogenesis during inﬂammation,  since recent studies 
revealed that HMGB1 induces sprouting and chemot-
axis of ECs and promotes angiogenesis in the chick 
embryo chorioallantoic membrane [25,  26].  However,  
there have been few studies on the eﬀects of HMGB1 
on angiogenesis in in vivo mammalian models.
　 In this study,  we examined the eﬀect of HMGB1 on 
angiogenesis in vivo using a matrigel system and dem-
onstrated that HMGB1 induced angiogenesis in a 
heparin-dependent manner.  This angiogenesis may 
occur through the expression of TNF-α and vascular 
endothelial growth factor-A120 (VEGF-A120) in the sur-
rounding areas of the matrigel.
Materials and Methods
　 Reagents. Matrigel is a mixture of basement 
membrane components extracted from Engelbreth-
Holm-Swarm (EHS) tumors inoculated in C57BL/6J 
mice.  The matrigel was prepared as previously 
described [27],  and was not supplemented with any 
growth factors.  Matrigel mainly contains laminin,  
collagen IV,  heparan sulfate proteoglycan and entac-
tin.  Since matrigel is a liquid at 4℃ and turns into a 
gel at 22-35℃,  we injected ice-cold matrigel solution 
into the backs of mice to allow the gel to form subcu-
taneously,  as shown in Fig.  1.  Anti-rat IgG goat 
polyclonal IgG-HRP was obtained from Santa Cruz 
Biotechnology (Santa Cruz,  CA,  USA).  Rat mono-
clonal anti-bovine HMGB1 antibody (#10-22) was 
produced as described previously [28].
　 Animals. Male C57BL/6J mice (24-26g,  
7-8wk) were obtained from the Department of Animal 
Resources of Okayama University.  All animal experi-
ments were performed according to the guidelines of 
Okayama University on animal experiments,  were 
approved by the Universityʼs committee on animal 
experimentation and conformed to the Guide for the 
Care and Use of Laboratory Animals published by the 
US National Institutes of Health (NIH Publication No.  
85-23,  revised 1996).  Mice were housed with a 12-h 
light-dark cycle at 22℃ with water and food ad libi-
tum.
　 Methods.
1. Expression and puriﬁcation of HMGB1.
　 Full-length human HMGB1 DNA was ampliﬁed by 
PCR using Cap Site cDNA dT from human microvas-
cular endothelial cells (Nippon Gene,  Tokyo,  Japan) 
and primers (forward 5ʼ-GCA GAA TTC ATG GGC 
AAA GGA GAT CCT A-3ʼ,  reverse 5ʼ-CAT CTC 
GAG TCA TTA TTC ATC ATC ATC ATC-3ʼ).  The 
full-length HMGB1 DNA fragment and pGEX-6p-1 
vector (GE Healthcare,  Little Chalfont,  England) 
were digested with EcoRI and XhoI (New England 
Biolabs,  Ipswich,  UK) restriction enzymes.  The DNA 
fragment was subcloned into the vector.  The recombi-
nant plasmids were transformed into E.coli strain 
BL21 (DE3) (Merck,  San Diego,  CA,  USA).  The 
transformants were incubated overnight at 37℃ to 
express the recombinant GST-HMGB1 in Overnight 
Express Instant TB medium (Merck).  E.coli extract 
containing GST-HMGB1 fusion proteins was applied 
to glutathione-Sepharose 4B and incubated for 1h at 
room temperature.  After extensive washing,  the gel 
bed was incubated with PreScission Protease for 3h 
at 4℃.  After brief centrifugation,  the supernatant 
containing GST-tag-deleted HMGB1 was collected and 
puriﬁed by gel ﬁltration chromatography using TSK-
gel 3000SWXL (Tosoh,  Tokyo,  Japan) [29].  Puriﬁed 
recombinant human HMGB1 protein was identiﬁed by 
SDS-PAGE [30] and Western blotting [31] with 
anti-HMGB1 monoclonal antibody (#10-22).  The ﬁnal 
HMGB1 preparation contained lipopolysaccharide 
(LPS) of less than 2.0pg/µg protein.
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2. In vivo matrigel plug assay.
　 At 4℃,  500µl of matrigel solution (8.4mg pro-
tein/ml) was mixed with PBS,  HMGB1 (2.5µg/ml,  
100nM),  heparin (320µg/ml,  64units/ml) (Sigma,  St.  
Louis,  MO,  USA),  heparin＋HMGB1,  human 
VEGF-A121 (185ng/ml,  6.5nM or 1.85µg/ml,  65nM) 
(Peprotech,  Rocky Hill,  CT,  USA),  human 
VEGF-A165 (250ng/ml,  6.5nM) (Peprotech),  human 
VEGF-A121＋heparin,  or human VEGF-A165＋hepa-
rin.  Male C57BL/6J mice were anesthetized with 
50ｵ N2O＋50ｵ O2 and the liquid matrigel mixture 
was injected subcutaneously into the back using a 25G 
needle.  The liquid matrigel mixture was solidiﬁed 
5-10min after injection (Fig.  1A).  Mice were sacri-
ﬁced at the indicated time points by cervical disloca-
tion and the matrigel plugs were recovered for analy-
sis of angiogenesis (Fig.  1B).
3. Quantiﬁcation of hemoglobin in matrigel.
　 The removed matrigel plugs were homogenized in 
10mM PBS (pH7.4) and centrifuged at 8,000×g for 
10min.  The hemoglobin contents in the supernatant 
were determined using a Hemoglobin B test kit (Wako,  
Osaka,  Japan) according to the manufacturerʼs instruc 
tions.
4. Immunohistochemistry.
　 Matrigel plugs were ﬁxed with 10ｵ formalin-0.1 M 
phosphate buﬀer and embedded in paraﬃn for HE and 
immunohistochemical stainings.  Immunohistochemical 
staining of CD31 was performed on 5µm matrigel 
sections with rabbit polyclonal anti-mouse CD31 anti-
body (Abcam,  Cambridge,  UK) followed by a second-
ary antibody,  anti-rabbit IgG goat IgG-HRP (Abcam).  
Immunoreactivity was visualized with 0.05ｵ 
3, 3ʼ-diaminobenzidine (Sigma) and 0.03ｵ H2O2.  
Counterstaining of nuclei was performed with Mayerʼs 
hematoxylin.  A negative control for immunohisto-
chemical staining was established by using the same 
concentration of normal rabbit IgG.  CD31-positive 
vessels were counted in 5 ﬁelds of a matrigel plug 
section at 400×magniﬁcation under a microscope.  
Microvessel density (MVD) was expressed as the 
number of microvessels per square millimeter.
5. HMGB1-heparin binding assay.
　 Heparin-Sepharose CL-6B (GE Healthcare) equili-
brated with PBS (10µl gel bed) was added to 200µl of 
HMGB1 (400µg/ml in PBS) solution and incubated 
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Fig. 1　 In vivo matrigel angiogenesis plug assay method.  (A) The injection point of matrigel into the mouse back is indicated.  For the 
PBS control,  matrigel was inoculated on the left side and for the other groups,  it was inoculated on the right side.  (B) The protocols of 
matrigel injection and sampling are shown.  (C) The sampling area of mouse skin for RT-PCR or real-time PCR is shown.
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for 16h at 4℃ with gentle shaking.  The reaction 
mixture was centrifuged at 8,000×g for 10min at 
4℃.  The supernatant was collected,  and the Sep-
harose was washed with PBS three times.  The 
supernatant and the resultant Sepharose gel samples 
were analyzed by SDS-PAGE to examine the binding 
of HMGB1 to heparin.
6. HMGB1 digestion assay.
　 Ten µl of HMGB1 (500µg/ml in PBS) was mixed 
with 2.5µl of heparin (32 or 320µg/ml) or PBS and 
incubated for 16h at 4℃.  Additionally,  the mixtures 
were mixed with 2.5µl of plasmin (20µg/ml) (Merck) 
and incubated for 1h at 25℃.  The reaction mixtures 
were analyzed by SDS-PAGE.
7. Determination of HMGB1 levels in matrigel 
using Western blotting.
　 A matrigel mixture containing PBS,  HMGB1 
(2.5µg/ml,  100nM) or heparin (320µg/ml,  64units/
ml)＋HMGB1 was injected subcutaneously into the 
backs of mice.  After 1,  3 or 10 days,  the matrigel 
plugs were recovered.  Matrigel homogenate corre-
sponding to 2.5mg wet weight was electrophoresed on 
polyacrylamide gel (12.5ｵ).  The samples were elec-
trophoretically blotted on polyvinylidine diﬂoride 
membrane (Bio-rad,  Hercules,  CA,  USA) at 45 V for 
2h by a transblot apparatus.  After the membrane was 
stained by ponceau S,  it was incubated with 10ｵ skim 
milk for 1h and was incubated overnight at 4℃ with 
mouse monoclonal anti-human HMGB1 antibody (R&D 
Systems,  Minneapolis,  MN,  USA).  After washing,  
the membrane was incubated with anti-mouse IgG goat 
polyclonal IgG-HRP (MBL,  Nagoya,  Japan) for 1h.  
The signals were ﬁnally visualized using an enhanced 
chemiluminescence system (Pierce Biotechnology,  
Rockford,  IL,  USA).
8. RT-PCR.
　 Total RNA was isolated from the mouse skin sur-
rounding the matrigel plug using an RNeasy ﬁbrous 
tissue mini kit (Qiagen,  Hilden,  Germany) (Fig.  1C).  
Complementary DNA was synthesized with a Takara 
RNA PCR kit Ver.  3.0 (Takara Bio,  Nagahama,  
Japan) according to the manufacturerʼs instructions.  
The PCR reaction was performed in a PCR Thermal 
Cycler (Takara Bio) using Ex Taq DNA polymerase 
HS (Takara Bio),  and sequence-speciﬁc primers 
(Table 1) according to the following program: after 
the initial denaturation at 94℃ for 3min,  ampliﬁ ca-
tion was done using X cycles of 94℃ for 30 sec,  Y℃ 
for 30 sec,  and 72℃ for 60 sec,  followed by a ﬁnal 
extension at 72℃ for 7min (X and Y are deﬁned in 
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Table 1　 Primer sequences,  annealing temperatures,  ampliﬁcation cycles and product sizes for RT-PCR
Primer Sequence 5ʼ-3ʼ Ampliﬁcationcycles (X)
Annealing
temperature (Y) Product size
GAPDH forward ACCACAGTCCATGCCATCAC 27 55°C 452bp
reverse TCCACCACCCTGTTGCTGTA
TNF-α forward TTCTGTCTACTGAACTTCGG 37 55°C 354bp
reverse GTATGAGATAGCAAATCGG
iNOS forward GCTTAGAGAACTCAACCAC 37 55°C 454bp
reverse GCTGCCCTCGAAGGTGAGC
eNOS forward CTGGACACCAGGACAACC 37 55°C 460bp
reverse GCTGCTGTGCGTAGCTCT
MMP-2 forward CCGTGGATGATGCTTTTGC 30 55°C 319bp
reverse CTGTATTCCCGACCGTTGA
MMP-9 forward TGCGCCACCACAGCCAAC 35 60°C 399bp
reverse GCCACGACCATACAGATAC
VEGFR-1 forward TGTGGAGAAACTTGGTGACCT 35 55°C 505bp
reverse TGGAGAACAGCAGGACTCCTT
VEGFR-2 forward AAGTGATTGAGGCAGACGCT 37 55°C 524bp
reverse TGATGCCAAGAACTCCAT
bFGF forward GACCCCAAGCGGCTCTACTGC 35 55°C 298bp
reverse GTGCCACATACCAACTGGAGT
VEGF-A forward GCGGGCTGCCTCGCAGT 37 55°C VEGF-A120 275bp
reverse TCACCGCCTTGGCTTGTCA VEGF-A164 407bp
VEGF-A188 479bp
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Table 1).  The PCR product was analyzed by electro-
phoresis on 2ｵ agarose gel.
9. Real-time quantitative PCR.
　 Real-time PCR was performed with a Light Cycler 
(Roche,  Basel,  Switzerland) according to the manu-
facturerʼs instructions.  Reaction mixtures contained 
cDNA template,  SYBR premix Ex Taq (Takara Bio,  
Shiga,  Japan),  and sequence-speciﬁc primers (Table 
2).
10. Statistical analysis.
　 All data are presented as the means±SEM.  
Diﬀerences between 2 groups were determined by 
ANOVA followed by Studentʼs t-test.  P values ＜0.05 
were considered statistically signiﬁcant.
Results
　 The eﬀect of HMGB1 and heparin on angio-
genesis in a matrigel plug assay. The matrigel 
mixture was injected subcutaneously into the backs of 
mice as shown in Fig.  1.  After 10 days,  the matrigel 
plugs were recovered as shown in Fig.  2.  It has been 
reported that 50 nuclei in the muscle tissue contain ～
25pg HMGB1 [32] and that LPS (100ng/ml)-stimu-
lated RAW264.7 cells (5×106 cells) release 10µg 
HMGB1 into the culture medium [6].  Given that an 
individual cell has a volume of 10µm3 and 10ｵ of the 
reported HMGB1 values represent extracellular 
release,  the estimated concentration of HMGB1 in the 
tissues will be 0.05 (muscle tissue) and 0.2 (RAW264.7 
cells) mg/ml,  respectively.  The concentrations of 
HMGB1 used in the present matrigel assay (2.5µg/
ml,  100nM) corresponded to 5ｵ and 1.25ｵ of these 
estimated values,  which would be readily attainable 
percentages under in vivo conditions in an inﬂammation 
area.  The concentration of heparin (320µg/ml,  
64units/ml) was determined according to the reports 
of Passaniti et al.  [33] and Isaji et al.  [34],  who 
used FGF and VEGF as angiogenic growth factors,  
respectively.  In the present study,  angiogenesis did 
not appear to be induced in the phosphate-buﬀered 
saline (PBS) control group.  Also in the groups 
treated with HMGB1 alone,  the matrigel did not show 
any change compared with the PBS control.  In the 
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Table 2　 Primer sequences, annealing temperatures and product sizes for real-time PCR
Primer Sequence 5ʼ-3ʼ Annealingtemperature Product size
GAPDH forward TGACGTGCCGCCTGGAGAAA 55°C 98bp
reverse AGTGTAGCCCAAGATGCCCTTCAG
TNF-α forward GACCCTCACACTCAGATCATCCTTCT 55°C 106bp
reverse GCGCTGGCTCAGCCACTC
iNOS forward GGCAGCCTGTGAGACCTTTG 55°C 72bp
reverse GCATTGGAAGTGAAGCGTTTC
eNOS forward CAACGCTACCACGAGGACATT 55°C 90bp
reverse CTCCTGCAAAGAAAAGCTCTGG
MMP-2 forward CCCCGATGCTGATACTGA 55°C 152bp
reverse CTGTCCGCCAAATAAACC
MMP-9 forward GCCCTGGAACTCACACGACA 55°C 85bp
reverse TTGGAAACTCACACGCCAGAAG
VEGFR-1 forward GGCAGACCAATACAATCCTAGATG 55°C 140bp
reverse ACCAGGGTAATTCCAGCTCATTT
VEGFR-2 forward CGACATAGCCTCCACTGTTTATG 55°C 109bp
reverse TTTGTTCTTGTTCTCGGTGATGT
bFGF forward CCCACCAGGCCACTTCAA 55°C 71bp
reverse GATGGATGCGCAGGAAGAA
VEGF-A120 forward GCCAGCACATAGAGAGAATGAGC 55°C 104bp
reverse CGGCTTGTCACATTTTTCTGG
VEGF-A164 forward GCCAGCACATAGAGAGAATGAGC 55°C 97bp
reverse CAAGGCTCACAGTGATTTTCTGG
VEGF-A188 forward GCCAGCACATAGAGAGAATGAGC 55°C 171bp
reverse AACAAGGCTCACAGTGAACGCT
5
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heparin-treated group,  there was a low level of angio-
genesis,  judging from the macroscopic color change.  
In the group treated with the combination of HMGB1 
and heparin,  the whole gel had red color heavily,  and 
a lot of the blood vessels seemed to be elongated into 
the center of the matrigel (Fig.  2A).  Next,  we deter-
mined the hemoglobin contents in the matrigel isolated 
from the back.  We obtained consistent results that 
reﬂected the color changes described above.  In the 
PBS or HMGB1 group,  little hemoglobin was 
detected in the matrigel.  In the heparin group,  there 
was a small amount of hemoglobin detected in the gel.  
In the group treated with the combination of HMGB1 
and heparin,  the hemoglobin content was signiﬁcantly 
increased (Fig.  2B).  Taken together,  these results 
indicate that angiogenesis was induced by the combina-
tion of HMGB1 and heparin in the matrigel plug assay.  
Ten days after inoculation,  a thin section of the 
matrigel was stained with hematoxylin-eosin (HE) 
(Fig.  3).  In the group treated with the combination of 
HMGB1 and heparin,  many inﬁltrating cells,  including 
leukocytes,  were observed in the gel (Fig.  3A,  panel 
d).  However,  few cells were observed in the gel sec-
tions from other groups (Fig.  3A,  panels a-c).  
Secondly,  immunostaining was performed with an 
antibody against CD31 that is a marker antigen of 
vascular endothelial cells.  Many cells with strong 
positively for CD31 were seen to be forming luminal 
structures in the sections from matrigels treated with 
the combination of HMGB1 and heparin (Fig.  3A,  
panel h).  The staining with anti-CD31 antibody was 
speciﬁc,  because staining with the control antibody did 
not reveal any structures in the same section.  In other 
groups,  few CD31-positive structures were observed 
(Fig.  3A,  panels e-g).  The number of CD31-positive 
luminal structures was counted in ﬁve random ﬁelds.  
In the group treated with HMGB1 and heparin,  the 
number of CD31-positive luminal structures was sig-
niﬁcantly increased in comparison with the number by 
treatment with HMGB1 or heparin alone (Fig.  3B).  
Taken together,  these results showed that the combi-
nation of HMGB1 and heparin induced the migration 
of vascular endothelial cells,  leading to the formation 
of new vessels in the matrigel.
　 HMGB1 binds to heparin. SDS-PAGE 
analysis following the incubation of HMGB1 with 
heparin-Sepharose gel revealed that HMGB1 was 
present in the heparin-Sepharose gel fraction but not 
in the supernatant fraction,  indicating that HMGB1 
formed a complex with heparin (Fig.  4A).
　 Degradation of HMGB1 by plasmin in the 
presence or absence of heparin. It has been 
reported that HMGB1 is a good substrate for plasmin 
[35].  Therefore,  we examined whether the complex 
formation between HMGB1 and heparin aﬀected the 
digestion eﬃciency by plasmin.  As shown in Fig.  4B,  
HMGB1 was resistant to plasmin digestion in the 
presence of heparin.  Even at a lower concentration 
(32µg/ml: 1/10 the concentration of heparin used in 
the matrigel assay),  the presence of heparin inhibited 
the degradation of HMGB1 by plasmin.
　 The determination of HMGB1 levels in 
matrigel. A matrigel mixture containing PBS,  
HMGB1 or heparin＋HMGB1 was injected subcuta-
neously into the backs of mice.  After 1,  3 or 10 days,  
the mice were sacriﬁced and the matrigel plugs were 
recovered.  HMGB1 was detected by Western blotting 
with anti-HMGB1 monoclonal antibody.  An equivalent 
amount of matrigel homogenate,  corresponding to 
2.5mg wet weight,  was loaded on each lane (Fig.  5A).  
In the group treated with HMGB1 and heparin,  
HMGB1 disappeared completely from the matrigels 3 
days after inoculation,  whereas there was no marked 
change in HMGB1 level in the group treated with 
HMGB1 alone throughout the 10-day measurement 
period (Fig.  5B).
　 The expression of angiogenesis-related 
mRNA in the mouse skin surrounding the 
matrigel plug. Total RNA was extracted from 
mouse skin surrounding the matrigel plug.  Ten days 
after the inoculation of matrigel,  RT-PCR for TNF-
α,  inducible nitric oxide synthase (iNOS),  endothelial 
nitric oxide synthase (eNOS),  MMP-2,  MMP-9,  
VEGF receptor-1 (VEGFR-1),  VEGFR-2,  basic 
ﬁbroblast growth factor (bFGF) and VEGF-A was 
performed with extracted RNA,  and the band density 
of each group was compared after agarose gel electro-
phoresis.  The TNF-α mRNA level was higher in the 
HMGB1 group than the PBS group.  The TNF-α 
mRNA level was signiﬁcantly higher in the group 
treated with HMGB1 and heparin than in that treated 
with HMGB1 alone.  The expression of TNF-α mRNA 
in the other groups was minimal under the same PCR 
conditions.  There were no signiﬁcant diﬀerences in 
iNOS,  eNOS,  MMP-2,  MMP-9,  VEGFR-1,  
VEGFR-2 or bFGF mRNA levels among the groups.  
254 Acta Med.  Okayama　Vol.  63,  No.  5Wake et al.
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Fig. 2　 Eﬀect of HMGB1 and heparin on angiogenesis in the matrigel assay.  (A) A matrigel mixture containing HMGB1 and heparin 
alone or in combination was injected subcutaneously into the backs of mice.  After 10 days,  the matrigel plugs were recovered.  Each 
group consisted of 6 mice.  Three representative cases are shown.  (B) The concentrations of hemoglobin in the matrigel plugs were deter-
mined.  The results are the means ± SEM of 6 matrigels.  ＊＊P＜0.01 compared with the PBS control group without any treatment.  ##P＜
0.01 compared with the group treated with heparin alone.
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Fig. 3　 Histological study of matrigel plugs.  (A) The matrigels were removed from the mouse back 10 days after inoculation and ﬁxed in 
10% formalin.  Paraﬃn-embedded sections of matrigel plug were stained by hematoxylin-eosin (a-d) and by anti-CD31 antibody (e-h).  The 
matrigels contained PBS (a,  e),  HMGB1 alone (b,  f),  heparin alone (c,  g),  or a combination of HMGB1 and heparin (d,  h).  Arrowheads 
indicate CD31-positive blood vessels.  The scale bar represents 100µm.  (B) CD31-positive vessels were counted in 5 ﬁelds of the matrigel 
plug section at 400×magniﬁcation under a microscope.  The microvessel density (MVD) was expressed as the number of microvessels per 
square millimeter.  The results are the means±SEM of 5 ﬁelds.  ＊＊P＜0.01 compared with the PBS control group.
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Fig. 4　 HMGB1 binding to heparin and its eﬀect on digestion by plasmin.  (A) HMGB1 was mixed with heparin-Sepharose and incubated 
for 16h at 4°C.  After incubation,  the supernatant (Sup) and the protein from the heparin-Sepharose gel (Gel) were electrophoresed on 
12% SDS-PAGE gel under a reducing condition,  followed by staining with Coomassie-blue.  (M) is a molecular weight marker.  (Con) rep-
resents the HMGB1 control.  (B) HMGB1 was preincubated with or without heparin for 16h at 4°C.  After preincubation,  the mixtures were 
subjected to plasmin digestion for 1h at 25°C.  The resultant mixtures were electrophoresed and the gels were stained as mentioned above.  
(Hep1) is HMGB1 incubated with 32µg/ml heparin and plasmin.  (Hep2) is HMGB1 incubated with 320µg/ml heparin and plasmin.
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Fig. 5　 Determination of HMGB1 levels in matrigel using Western blotting.  A Matrigel mixture containing PBS,  HMGB1 (2.5µg/ml,  
100nM) or heparin (320µg/ml,  64units/ml)＋HMGB1 was injected subcutaneously into the backs of mice.  After 1,  3 and 10 days,  the 
matrigel plugs were recovered.  The matrigel plugs were homogenized and an amount of homogenate corresponding to 2.5mg wet weight of 
matrigel was loaded on each lane.  (A) Ponseau S staining of the PVDF membrane.  (B) Detection of HMGB1 in matrigel.  (－) negative 
control; matrigel contains PBS alone.  (＋) positive control; recombinant human HMGB1.
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We also examined the mRNA levels of 3 kinds of 
VEGF isoform (VEGF-A120,  VEGF-A164,  
VEGF-A188).  There were no signiﬁcant diﬀerences in 
the mRNA levels of VEGF-A164 or VEGF-A188 among 
the groups.  However,  the VEGF-A120 mRNA expres-
sion level was signiﬁcantly higher in the group treated 
with HMGB1 and heparin than in the PBS control and 
heparin-alone groups (Fig.  6).  Consequently,  it was 
revealed that the combination of HMGB1 and heparin 
selectively increased the expressions of the mRNAs of 
TNF-α and VEGF-A120.
　 Quantiﬁcation of angiogenesis-related mRNA 
in mouse skin. The mRNA expression levels of 
cytokines,  MMPs and growth factors were quantiﬁed 
by real-time PCR using the RNA extracted from 
mouse skin surrounding the matrigel plug (Figs.  7A 
and B).  The expression of TNF-α mRNA was signiﬁ-
cantly higher in the group treated with HMGB1 alone 
than in that treated with PBS alone.  In addition,  the 
TNF-α mRNA expression was signiﬁcantly higher in 
the group treated with the combination of HMGB1 and 
heparin than in that treated with HMGB1 alone (Fig.  
7A).  In regard to the expressions of iNOS,  eNOS,  
MMP-2,  MMP-9,  VEGFR-1,  VEGFR-2 and bFGF,  
there were no diﬀerences among the groups,  in agree-
ment with the RT-PCR ﬁndings.  In regard to the 
VEGF-A mRNA expression level,  VEGF-A120 mRNA 
was signiﬁcantly higher in the group treated with the 
combination of HMGB1 and heparin than in the other 
groups,  whereas the expression of mRNAs for 
VEGF-A164 and VEGF-A188 was not diﬀerent among 
the groups (Fig.  7B).  Collectively,  these ﬁndings 
demonstrated that the combination treatment with 
HMGB1 and heparin increased the mRNA expression 
levels of TNF-α and VEGF-A120 signiﬁcantly.
　 The eﬀect of VEGF and heparin on angio-
genesis in the matrigel plug assay. It was 
apparent that the combination of VEGF-A165 (250ng/
ml,  6.5nM) and heparin also induced angiogenesis 10 
days after inoculation of matrigel (Fig.  8).  The com-
bination of VEGF-A121 (185ng/ml,  6.5nM) and hepa-
rin did not induce angiogenesis significantly.  
VEGF-A165 alone also did not induce angiogenesis.  A 
tenfold higher concentration (1.85µg/ml,  65nM) of 
VEGF-A121 alone did not induce angiogenesis in the 
matrigel plug,  but induced a low level of angiogenesis 
in the skin surrounding it (Fig.  9).
Discussion
　 In the present study,  it was clearly demonstrated 
that the combination of HMGB1 and heparin induced 
marked angiogenesis in the matrigel plug assay,  
accompanied with many CD31-positive blood vessels in 
the gel,  whereas HMGB1 or heparin alone did not.  
Since matrigel,  the basement membrane components 
puriﬁed from murine EHS tumors,  mainly contains 
laminin,  collagen IV,  heparan sulfate proteoglycan 
and entactin [27] and HMGB1 has been repeatedly 
reported to bind to heparin and heparan sulfate pro-
teoglycan [36-38],  HMGB1 is assumed to bind to 
heparan sulfate proteoglycan in the matrigel plug in 
the absence of heparin.  For this reason,  we expected 
that the diﬀusion of HMGB1 to the surrounding tissue 
would be suppressed and HMGB1 would fail to leave 
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Fig. 6　 Expression of mRNAs in mouse skin surrounding the 
matrigel plug.  (A) Total RNA was isolated from the skin above the 
matrigel plug at 10 days after matrigel injection into the backs of 
mice.  RT-PCR was performed using the primers indicated in Table 
1.  Representative results from 3 mice are shown.
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the matrigel and stimulate the tissue surrounding the 
matrigel plug.  And in fact,  this notion was supported 
by the results showing the presence of initial levels of 
HMGB1 in the matrigel up to 10 days after inocula-
tion.  In contrast,  HMGB1 completely disappeared 
from the matrigel in the presence of heparin 3 days 
after inoculation.  Thus,  the addition of heparin to 
HMGB1 probably allows the HMGB1 to diﬀuse to the 
surrounding tissue through its complexation with 
heparin.  The HMGB1-heparin complex probably does 
not bind to the heparan sulfate proteoglycan in matri-
gel or on cell surface,  and thus it can bind to the 
receptors of HMGB1 (e.g.,  RAGE,  TLR-2 and TLR-
4) [11] on the surface of macrophages and vascular 
endothelial cells.  Since VEGF,  a well-known angio-
genic factor,  has been reported to become resistant to 
degradation by proteinases upon complexation with 
heparin [1] and HMGB1 is known to be degraded by 
plasmin eﬃciently [35],  we examined whether 
HMGB1 degradation by plasmin may be changed after 
the complex formation with heparin.  As shown in Fig.  
4B,  the degradation of HMGB1 by plasmin was sig-
niﬁcantly retarded in the presence of heparin,  sug-
gesting the acquirement of resistance to enzymatic 
digestion.  Together,  these results show that complex 
formation with heparin enabled HMGB1 to acquire 
resistance to proteolytic degradation and to diﬀuse to 
the surrounding tissues,  thus leading to angiogenenic 
activity.
　 We observed that HMGB1 in combination with 
heparin increased the expression of TNF-α and 
VEGF-A120 signiﬁcantly.  TNF-α has been reported to 
induce IL-8,  VEGF and bFGF expression in human 
microvascular endothelial cells.  Also,  TNF-α facili-
tates tube formation in HMVEC in vitro and angiogen-
esis on chick chorioallantoic membranes and rat cor-
neas in vivo.  Thus,  TNF-α may have a direct 
angiogenic action as well as an indirect action through 
IL-8,  VEGF and bFGF [39-41].  In the present 
study,  HMGB1 alone also induced the expression of 
TNF-α mRNA but did not induce angiogenesis.  The 
TNF-α expression level induced by HMGB1 alone may 
not be suﬃcient to induce angiogenesis.  However,  the 
high expression level of TNF-α mRNA induced by the 
combination of HMGB1 and heparin is thought to be 
suﬃcient to induce angiogenesis.  Moreover,  in the 
matrigel plug assay,  TNF-α has been reported to 
induce angiogenesis in a heparin-dependent manner 
[42].  Taken together,  these results suggest that 
TNF-α induced by HMGB1 in complex with heparin 
may contribute to angiogenesis to some degree.  Five 
kinds of isoforms of VEGF-A are presently known to 
exist: VEGF-A 120/121,  144/145,  164/165,  188/ 
189,  and 205/206 (murine/human).  VEGF-A120/121,  
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Fig. 7　 Quantiﬁcation of mRNA expression in mouse skin surrounding matrigel plug.  Total RNA was isolated from mouse the skin above 
the matrigel plug at 10 days after matrigel injection into the backs of mice.  Real-time PCR was performed using the primers indicated in 
Table 2.  The expression of GAPDH was used to normalize cDNA levels.  (A) The columns represent the following: ,  TNF-α; ,  
iNOS; , eNOS; , MMP-2; , MMP-9.  (B) The columns represent the followings; ,  VEGF-A120; ,  VEGF-A164; ,  VEGF-A188;  
,  bFGF; ,  VEGFR-1; ,  VEGFR-2.  The results are the means±SEM for 3 animals.  ＊P＜0.05,  ＊＊P＜0.01 compared with the control 
group in the absence of HMGB1 and heparin.  #P＜0.05 compared with the group treated with HMGB1 alone.  †P＜0.05 compared with the 
group treated with heparin alone.
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VEGF-A144/145 and VEGF-A188/189 have been reported 
to be expressed widely in many kinds of tissue.  Among 
these three isoforms,  VEGF-A120/121 and VEGF-A164/165 
are known to induce angiogenesis [3].  VEGF-A120/121 
is the only isoform lacking heparin-binding ability,  
because it does not have exon 6 and 7 [3].  Taken 
together,  these ﬁndings suggest that HMGB1 in com-
plex with heparin induces angiogenesis through the 
expression of TNF-α and VEGF-A120.
　 Interestingly,  VEGF-A165 with a heparin-binding 
domain showed a pattern of activities similar to 
HMGB1; that is,  both showed heparin-dependent 
angiogenic activity.  This implies that the heparin-
binding of VEGF-A165 may also be important for diﬀu-
sion of VEGF-A165 from matrigel and protection from 
proteolytic digestion [1] in this model.  Although 
VEGF-A121 lacking heparin-binding ability did not 
show any angiogenic activity even in the presence of 
heparin,  a high concentration of VEGF-A121 (1.85µg/
ml,  65nM) induced a low level of angiogenesis in the 
skin surrounding the matrigel plug.  The low angio-
genic activity of VEGF-A121 might be ascribed to 
degradation by proteases during diﬀusion.  Thus it is 
likely that the VEGF-A120 produced in the tissue sur-
rounding the matrigel plug by the combination of 
HMGB1 and heparin works on vascular endothelial 
cells and macrophages in an autocrine and a paracrine 
manner at relatively higher concentrations.  This may 
limit the proteolytic inactivation of VEGF-A120 
induced by HMGB1 and heparin.  Further studies will 
be needed to investigate this point.
　 In inﬂammation and tissue injury,  HMGB1 is 
released from the nuclei of necrotic or damaged cells.  
The released HMGB1 functions as a proinﬂammatory 
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Fig. 8　 Eﬀect of VEGF on the angiogenesis in the presence or absence of heparin in the matrigel assay.  (A) A matrigel mixture contain-
ing VEGF (VEGF-A121 185ng/ml,  6.5nM; VEGF-A165 250ng/ml,  6.5nM) and heparin alone or in combination was injected subcutaneously 
into the backs of mice.  After 10 days,  the matrigel plugs were recovered.  Each group consisted of 6 mice.  (B) The concentrations of 
hemoglobin in the matrigel plugs were determined.  The results are the means±SEM of 6 matrigels.  ＊＊P＜0.01 compared with the PBS 
control group without any addition.  ##P＜0.01 compared with the group treated with heparin alone.  ††P＜0.01 compared with the group 
treated with VEGF-A165 alone.
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cytokine through plural pathways [11].  However,  
HMGB1 trapped by heparan sulfate in the extracel-
lular matrix cannot diﬀuse to surrounding areas.  Mast 
cells secrete heparin [43],  and this heparin can com-
pete for heparan sulfate followed by the de-anchoring 
of HMGB1 from the extracellular matrix.  On the 
other hand,  macrophages and mast cells secrete hepa-
ranase [44,  45] and can degrade the heparan sulfate 
on which HMGB1 is anchored.  HMGB1 bound to 
heparin or cleaved heparan sulfate can diﬀuse to 
larger surrounding areas and cannot be degraded eas-
ily by proteinase,  allowing HMGB1 to bind to its 
receptors on macrophages and ECs.  These events may 
play a role in tumor growth.  It has been demonstrated 
that many types of cancer cells produce HMGB1 and 
release it extracellularly [16-20],  and that mast cells 
and macrophages are abundant in the invasive front of 
tumors [46,  47].  Accumulating evidence indicates 
that VEGF production is involved in the angiogenesis 
of several cancers.  Therefore,  it is speculated that 
HMGB1 released from tumor cells may contribute to 
the angiogenic activity through the production of 
VEGF-A120 in the areas surrounding tumor tissues.
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Fig. 9　 Eﬀect of high concentration VEGF-A121 alone on the angiogenesis.  (A) A matrigel mixture containing a high concentration of 
VEGF-A121 (1.85µg/ml,  65nM) was injected subcutaneously into the backs of mice.  After 10 days,  the matrigel plugs were recovered.  
Each group consisted of 6 mice.  (B) The concentrations of hemoglobin in the matrigel plugs were determined.  The results are the means
±SEM of 6 matrigels.  (C) A skin sample from the region surrounding the matrigel plug containing PBS or a high concentration of 
VEGF-A121 is shown.
12
Acta Medica Okayama, Vol. 63 [2009], Iss. 5, Art. 5
http://escholarship.lib.okayama-u.ac.jp/amo/vol63/iss5/5
Research to H.W.,  from the Japan Society for the Promotion of Science 
(JSPS No.  21390071; JSPS No.  21659141) to M.N.  and (JSPS No.  
21590594) to K.L.  and from the Mitsui Sumitomo Insurance Welfare 
Foundation to S.M.
References
 1. Colville-Nash PR and Scott DL: Angiogenesis and rheumatoid 
arthritis: pathogenic and therapeutic implications.  Ann Rheum Dis 
(1992) 51: 919-925.
 2. Folkman J and Shing Y: Angiogenesis.  J Biol Chem (1992) 
267: 10931-10934.
 3. Hoeben A,  Landuyt B,  Highley MS,  Wildiers H,  Van Oosterom AT 
and De Bruijn EA: Vascular endothelial growth factor and angio-
genesis.  Pharmacol Rev (2004) 56: 549-580.
 4. Bustin M: Regulation of DNA-dependent activities by the func-
tional motifs of the high-mobility-group chromosomal proteins.  Mol 
Cell Biol (1999) 19: 5237-5246.
 5. Scaﬃdi P,  Misteli T and Bianchi ME: Release of chromatin pro-
tein HMGB1 by necrotic cells triggers inﬂammation.  Nature (2002) 
418: 191-195.
 6. Wang H,  Bloom O,  Zhang M,  Vishnubhakat JM,  Ombrellino M,  
Che J,  Frazier A,  Yang H,  Ivanova S,  Borovikova L,  Manogue 
KR,  Faist E,  Abraham E,  Andersson J,  Andersson U,  Molina PE,  
Abumrad NN,  Sama A and Tracey KJ: HMG-1 as a late mediator 
of endotoxin lethality in mice.  Science (1999) 285: 248-251.
 7. Wang H,  Yang H,  Czura CJ,  Sama AE and Tracey KJ: HMGB1 
as a late mediator of lethal systemic inﬂammation.  Am J Respir 
Crit Care Med (2001) 164: 1768-1773.
 8. Yuan F,  Gu L,  Guo S,  Wang C and Li GM: Evidence for involve-
ment of HMGB1 protein in human DNA mismatch repair.  J Biol 
Chem (2004) 279: 20935-20940.
 9. Yotov WV and St-Arnaud R: Nucleotide sequence of a mouse 
cDNA encoding the nonhistone chromosomal high mobility group 
protein-1 (HMG1).  Nucleic Acids Res (1992) 20: 3516.
10. Walker JM,  Gooderham K,  Hastings JR,  Mayes E and Johns 
EW: The primary structures of non-histone chromosomal proteins 
HMG 1 and 2.  FEBS Lett (1980) 122: 264-270.
11. Yamada S and Maruyama I: HMGB1,  a novel inﬂammatory 
cytokine.  Clin Chim Acta (2007) 375: 36-42.
12. Huttunen HJ,  Fages C,  Kuja-Panula J,  Ridley AJ and Rauvala 
H: Receptor for advanced glycation end products-binding COOH-
terminal motif of amphoterin inhibits invasive migration and metas-
tasis.  Cancer Res (2002) 62: 4805-4811.
13. Karlsson S,  Pettilä V,  Tenhunen J,  Laru-Sompa R,  Hynninen M 
and Ruokonen E: HMGB1 as a predictor of organ dysfunction and 
outcome in patients with severe sepsis.  Intensive Care Med (2008) 
34: 1046-1053.
14. Porto A,  Palumbo R,  Pieroni M,  Aprigliano G,  Chiesa R,  Sanvito F,  
Maseri A and Bianchi ME: Smooth muscle cells in human athero-
sclerotic plaques secrete and proliferate in response to high mobil-
ity group box 1 protein.  FASEB J (2006) 20: 2565-2566.
15. Taniguchi N,  Kawahara K,  Yone K,  Hashiguchi T,  Yamakuchi M,  
Goto M,  Inoue K,  Yamada S,  Ijiri K,  Matsunaga S,  Nakajima T,  
Komiya S and Maruyama I: High mobility group box chromosomal 
protein 1 plays a role in the pathogenesis of rheumatoid arthritis as 
a novel cytokine.  Arthritis Rheum (2003) 48: 971-981.
16. Kuniyasu H,  Sasaki T,  Sasahira T,  Ohmori H and Takahashi 
T: Depletion of tumor-inﬁltrating macrophages is associated with 
amphoterin expression in colon cancer.  Pathobiology (2004) 
71: 129-136.
17. Kuniyasu H,  Chihara Y and Kondo H: Diﬀerential eﬀects between 
amphoterin and advanced glycation end products on colon cancer 
cells.  Int J Cancer (2003) 104: 722-727.
18. Kawahara N,  Tanaka T,  Yokomizo A,  Nanri H,  Ono M,  Wada M,  
Kohno K,  Takenaka K,  Sugimachi K and Kuwano M: Enhanced 
coexpression of thioredoxin and high mobility group protein 1 
genes in human hepatocellular carcinoma and the possible associ-
ation with decreased sensitivity to cisplatin.  Cancer Res (1996) 
56: 5330-5333.
19. Taguchi A,  Blood DC,  del Toro G,  Canet A,  Lee DC,  Qu W,  
Tanji N,  Lu Y,  Lalla E,  Fu C,  Hofmann MA,  Kislinger T,  Ingram M,  
Lu A,  Tanaka H,  Hori O,  Ogawa S,  Stern DM and Schmidt AM:  
Blockade of RAGE-amphoterin signalling suppresses tumour growth 
and metastases.  Nature (2000) 405: 354-360.
20. Choi YR,  Kim H,  Kang HJ,  Kim NG,  Kim JJ,  Park KS,  Paik YK,  
Kim HO and Kim H: Overexpression of high mobility group box 1 
in gastrointestinal stromal tumors with KIT mutation.  Cancer Res 
(2003) 63: 2188-2193.
21. Sappington PL,  Yang R,  Yang H,  Tracey KJ,  Delude RL and Fink 
MP: HMGB1 B box increases the permeability of Caco-2 entero-
cytic monolayers and impairs intestinal barrier function in mice.  
Gastroenterology (2002) 123: 790-802.
22. Park JS,  Arcaroli J,  Yum HK,  Yang H,  Wang H,  Yang KY,  Choe 
KH,  Strassheim D,  Pitts TM,  Tracey KJ and Abraham E: Activa-
tion of gene expression in human neutrophils by high mobility 
group box 1 protein.  Am J Physiol Cell Physiol (2003) 284: C870-
879.
23. Yu M,  Wang H,  Ding A,  Golenbock DT,  Latz E,  Czura CJ,  
Fenton MJ,  Tracey KJ and Yang H: HMGB1 signals through toll-
like receptor (TLR) 4 and TLR2.  Shock (2006) 26: 174-179.
24. Andersson U,  Wang H,  Palmblad K,  Aveberger AC,  Bloom O,  
Erlandsson-Harris H,  Janson A,  Kokkola R,  Zhang M,  Yang H 
and Tracey KJ: High mobility group 1 protein (HMG-1) stimulates 
proinﬂammatory cytokine synthesis in human monocytes.  J Exp 
Med (2000) 192: 565-570.
25. Schlueter C,  Weber H,  Meyer B,  Rogalla P,  Röser K,  Hauke S 
and Bullerdiek J: Angiogenetic signaling through hypoxia:  
HMGB1: an angiogenetic switch molecule.  Am J Pathol (2005) 
166: 1259-1263.
26. Mitola S,  Belleri M,  Urbinati C,  Coltrini D,  Sparatore B,  Pedrazzi 
M,  Melloni E and Presta M: Cutting edge: extracellular high 
mobility group box-1 protein is a proangiogenic cytokine.  J Immu-
nol (2006) 176: 12-15.
27. Kleinman HK,  McGarvey ML,  Hassell JR,  Star VL,  Cannon FB,  
Laurie GW and Martin GR: Basement membrane complexes with 
biological activity.  Biochemistry (1986) 25: 312-318.
28. Liu K,  Mori S,  Takahashi HK,  Tomono Y,  Wake H,  Kanke T,  
Sato Y,  Hiraga N,  Adachi N,  Yoshino T and Nishibori M: Anti-high 
mobility group box 1 monoclonal antibody ameliorates brain infarc-
tion induced by transient ischemia in rats.  FASEB J (2007) 
21: 3904-3916.
29. Li J,  Wang H,  Mason JM,  Levine J,  Yu M,  Ulloa L,  Czura CJ,  
Tracey KJ and Yang H: Recombinant HMGB1 with cytokine-stimu-
lating activity.  J Immunol Methods (2004) 289: 211-223.
30. Laemmli UK: Cleavage of structural proteins during the assembly 
of the head of bacteriophage T4.  Nature (1970) 227: 680-685.
31. Towbin H,  Staehelin T and Gordon J: Electrophoretic transfer of 
proteins from polyacrylamide gels to nitrocellulose sheets:  
procedure and some applications.  Proc Natl Acad Sci U S A 
(1979) 76: 4350-4354.
261HMGB1-Heparin Complex-Induced AngiogenesisOctober 2009
13
Wake et al.: High mobility group box 1 complexed with heparin induced angiogen
Produced by The Berkeley Electronic Press, 2009
32. Palumbo R,  Sampaolesi M,  De Marchis F,  Tonlorenzi R,  
Colombetti S,  Mondino A,  Cossu G and Bianchi ME: Extracellular 
HMGB1,  a signal of tissue damage,  induces mesoangioblast 
migration and proliferation.  J Cell Biol (2004) 164: 441-449.
33. Passaniti A,  Taylor RM,  Pili R,  Guo Y,  Long PV,  Haney JA,  
Pauly RR,  Grant DS and Martin GR: A simple,  quantitative 
method for assessing angiogenesis and antiangiogenic agents 
using reconstituted basement membrane,  heparin,  and ﬁbroblast 
growth factor.  Lab Invest (1992) 67: 519-528.
34. Isaji M,  Miyata H,  Ajisawa Y,  Takehana Y and Yoshimura 
N: Tranilast inhibits the proliferation,  chemotaxis and tube forma-
tion of human microvascular endothelial cells in vitro and angio-
genesis in vivo.  Br J Pharmacol (1997) 122: 1061-1066.
35. Parkkinen J,  Raulo E,  Merenmies J,  Nolo R,  Kajander EO,  
Baumann M and Rauvala H: Amphoterin,  the 30-kDa protein in a 
family of HMG1-type polypeptides.  Enhanced expression in trans-
formed cells,  leading edge localization,  and interactions with plas-
minogen activation.  J Biol Chem (1993) 268: 19726-19738.
36. Salmivirta M,  Rauvala H,  Elenius K and Jalkanen M: Neurite 
growth-promoting protein (amphoterin,  p30) binds syndecan.  Exp 
Cell Res (1992) 200: 444-451.
37. Milev P,  Chiba A,  Häring M,  Rauvala H,  Schachner M,  Ranscht B,  
Margolis RK and Margolis RU: High aﬃnity binding and overlap-
ping localization of neurocan and phosphacan/protein-tyrosine 
phosphatase-ζ/β with tenascin-R,  amphoterin,  and the heparin-
binding growth-associated molecule.  J Biol Chem (1998) 
273: 6998-7005.
38. Rauvala H,  Huttunen HJ,  Fages C,  Kaksonen M,  Kinnunen T,  
Imai S,  Raulo E and Kilpeläinen I: Heparin-binding proteins 
HB-GAM (pleiotrophin) and amphoterin in the regulation of cell 
motility.  Matrix Biol (2000) 19: 377-387.
39. van Beijnum JR,  Buurman WA and Griﬃoen AW:  Convergence 
and ampliﬁcation of toll-like receptor (TLR) and receptor for 
advanced glycation end products (RAGE) signaling pathways via 
high mobility group B1 (HMGB1).  Angiogenesis (2008) 11: 91-99.
40. Leibovich SJ,  Polverini PJ,  Shepard HM,  Wiseman DM,  Shively 
V and Nuseir N: Macrophage-induced angiogenesis is mediated 
by tumour necrosis factor-alpha.  Nature (1987) 329: 630-632.
41. Yoshida S,  Ono M,  Shono T,  Izumi H,  Ishibashi T,  Suzuki H and 
Kuwano M: Involvement of interleukin-8,  vascular endothelial 
growth factor,  and basic ﬁbroblast growth factor in tumor necrosis 
factor alpha-dependent angiogenesis.  Mol Cell Biol (1997) 
17: 4015-4023.
42. Montrucchio G,  Lupia E,  Battaglia E,  Passerini G,  Bussolino F,  
Emanuelli G and Camussi G: Tumor necrosis factor alpha-induced 
angiogenesis depends on in situ platelet-activating factor biosyn-
thesis.  J Exp Med (1994) 180: 377-382.
43. Hiromatsu Y and Toda S: Mast cells and angiogenesis.  Microsc 
Res Tech (2003) 60: 64-69.
44. Gingis-Velitski S,  Zetser A,  Flugelman MY,  Vlodavsky I and Ilan 
N: Heparanase induces endothelial cell migration via protein 
kinase B/Akt activation.  J Biol Chem (2004) 279: 23536-23541.
45. Cohen-Mazor M,  Sela S,  Mazor R,  Ilan N,  Vlodavsky I,  Rops AL,  
van der Vlag J,  Cohen HI and Kristal B: Are primed polymorpho-
nuclear leukocytes contributors to the high heparanase levels in 
hemodialysis patients? Am J Physiol Heart Circ Physiol (2008) 
294: H651-658.
46. Yoshii M,  Jikuhara A,  Mori S,  Iwagaki H,  Takahashi HK,  
Nishibori M and Tanaka N: Mast cell tryptase stimulates DLD-1 
carcinoma through prostaglandin- and MAP kinase-dependent man-
ners.  J Pharmacol Sci (2005) 98: 450-458.
47. Halin S,  Rudolfsson SH,  Van Rooijen N and Bergh A: Extratumoral 
macrophages promote tumor and vascular growth in an orthotopic 
rat prostate tumor model.  Neoplasia (2009) 11: 177-186.
262 Acta Med.  Okayama　Vol.  63,  No.  5Wake et al.
14
Acta Medica Okayama, Vol. 63 [2009], Iss. 5, Art. 5
http://escholarship.lib.okayama-u.ac.jp/amo/vol63/iss5/5
